Top News
Home >> Top news >> Abbott marketing Alinity systems in the U.S.

Abbott marketing Alinity systems in the U.S.

Print Friendly, PDF & Email

June 11, 2018—Abbott has introduced the Alinity family of diagnostic systems in the United States. The portfolio of screening systems includes immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening, and molecular diagnostics.

Among the features of Alinity are a compact design; flexibility and scalability; proprietary lock-and-key reagent bottles that only fit in designated positions; an integrated, common interface across instruments; and continuous accessibility, which allows the lab to run any test at any time and replace reagents without stopping the instrument.

“The Alinity family of systems combined with AlinIQ — a first-of-its-kind, holistic suite of professional services that combines expertise with process analysis and informatics — helps labs and hospital systems solve some of their most pressing challenges to deliver better patient care with fewer resources,” according to a press release from Abbott.

More than 1,000 Alinity instruments have been ordered or installed globally, Abbott reports. The company will kick off its introduction of Alinity in the United States with the Alinity c clinical chemistry system and Alinity i immunoassay system, which can operate individually or as an integrated system.

More top news


Check Also


PGx testing: recommended alleles for CYP2C19 panels

August 2018—After more than a year of gathering information and deliberating, members of the Association for Molecular Pathology Pharmacogenomics Working Group have issued the first in what will be a series of recommendations to standardize pharmacogenetic testing.